CLINICAL_TRIALS ClinicalTrials.gov record update

A Non-randomized, Open-label, Multi-center, Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03458728
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:26.278144+00:00
Published At: 2023-12-04T00:00:00+00:00
Record Updated At: 2023-12-04
Results Posted At: 2023-12-04
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Relapsed or Refractory Solid Tumors or Lymphoma in Children", "Neuroblastoma", "Osteosarcoma", "Rhabdomyosarcoma", "Ewing Sarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-12-04"
protocolSection.identificationModule.nctId: "NCT03458728"
protocolSection.identificationModule.officialTitle: "A Non-randomized, Open-label, Multi-center, Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-12-04"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.